Table 2.
Scan data
| Patients (n = 32) | Mean ± SD | Number | |||
|---|---|---|---|---|---|
| Malignant findings in PET/CT | FDG | FAPI-46 | |||
| CR < 4.0 | CR > 4.0 | CR < 4.0 | CR > 4.0 | ||
| Tumors (n = 32) | 2 | 30 | 2 | 30 | |
| Metastasis (n = 25) | 7 | 18 | 1 | 24 | |
| Lymph node metastasis | 6 | 11 | 1 | 16 | |
| Liver metastasis | 1 | 1 | 0 | 2 | |
| Gastric metastasis / second tumor | 0 | 3 | 0 | 3 | |
| Bone metastasis | 0 | 1 | 0 | 1 | |
| Adrenal gland metastasis | 0 | 1 | 0 | 1 | |
| Muscle metastasis | 0 | 1 | 0 | 1 | |
| Time between injection FAPI and Scan (min) | 21.8 ± 22.4 | ||||
| Time between injection FDG and Scan (min) | 64.8 ± 14.2 | ||||
Injection data of FAPI-46/FDG and count of malignant findings. FTV measurement was performed by using a fixed threshold of CR 4.0 or in case of dual-tracer PET/CT a CR-adapted threshold as described before. Here, we show an overview of all lesions with a CR > 4.0 that are thus measurable for FTV. SD = standard deviation, CR = count rate, FDG = fluorodeoxy-D-glucose, FAPI = fibroblast activation protein inhibitor